• The Peptique is LIVE! Go to https://thepeptique.com/ to get all your research peptides .As a loyal listener use the discount code POD15 to get 15% off the entire line of products.
• Have questions? Feel free to reach out to me: [email protected]
• Want to get started the right way, but don't know where to start. Email me [email protected] to set up a 30 minute $100 session to get your personalized protocol. A special discount on your first order will be included. These spots fill up fast so schedule today!
• Want the free peptide guide? Email me [email protected] and comment Guide and I'll shoot it right over!
• Follow me on instagram @westwellnessatx

Takeaways:

• This podcast episode marks the 50th installment, showcasing significant growth and listener engagement.
• The primary focus of today's discussion centers on the relationship between NAD and cancer risk.
• NAD is crucial for cellular functions including energy production, DNA repair, and immune response.
• Current research presents mixed results regarding NAD's role in cancer, demanding further investigation and caution.
• NAD supplementation may not inherently cause cancer but could influence existing cancer cell behavior.
• Listeners are encouraged to conduct their own research and consider their personal health situations regarding NAD usage.

Research Links

NAD+ biology, aging, immunity, DNA repair

• Covarrubias et al. “NAD+ metabolism and its roles in cellular processes during ageing” (review). https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/ PMC
• Ghanem et al. “Inhibitors of NAD+ Production in Cancer Treatment” (NAMPT/NAPRT review). https://pmc.ncbi.nlm.nih.gov/articles/PMC10889166/ PMC
• Manickam et al. “Nampt: a new therapeutic target for modulating NAD metabolism in cancer and inflammation” (2025 review). https://cdnsciencepub.com/doi/10.1139/cjpp-2024-0400 Canadian Science Publishing

Extracellular metabolism and cellular uptake (do IVs reach cells?)

• Gasparrini et al. “Enzymology of extracellular NAD metabolism” (ectoenzymes; NR/NMN/NAM import). https://pmc.ncbi.nlm.nih.gov/articles/PMC8038981/ PMC
• Yusri et al. “The role of NAD+ metabolism and its modulation” (2025 review; NR via ENTs; NMN dephosphorylation; SLC12A8 debate). https://www.nature.com/articles/s44324-025-00067-0 Nature
• Yaku et al. “NR and NMN: similarities and differences” (2025 perspective; NMN→NR conversion before uptake). https://www.science.org/doi/10.1126/sciadv.adr1538 Science

Human IV NAD+ / IV NR data

• Grant et al. “A Pilot Study… during a 6-hour intravenous infusion of NAD+” (750 mg IV NAD+, plasma/urine kinetics, rapid early clearance, metabolite rise, tolerability). https://pmc.ncbi.nlm.nih.gov/articles/PMC6751327/PMC
• Randomized pilot: IV nicotinamide riboside (NR) 500 mg—acute safety. https://www.medrxiv.org/content/10.1101/2024.06.06.24308565v1.full-text MedRxiv

Cancer signals—mixed preclinical findings

• Maric et al. “Bioluminescent probe… NR supplementation increased TNBC prevalence and brain metastases” (mouse). https://pubmed.ncbi.nlm.nih.gov/36371959/ PubMed
• Jiang et al. “NAD+ supplementation limits TNBC metastasis” (PDX model). https://pubmed.ncbi.nlm.nih.gov/36690678/ PubMed
• Mogol et al. “Targeting NAD+ Metabolism: Preclinical insights” (2024 endocrine review; tumor NAD+ dependencies). https://academic.oup.com/endo/article/165/5/bqae043/7639411 Oxford Academic

Clinical-context commentary (regulatory and claims landscape)

• Guardian report on UK clinics advertising NAD+ infusions for addiction without robust evidence. https://www.theguardian.com/society/2025/feb/23/its-not-ethical-and-its-not-medical-how-uk-rehab-clinics-are-cashing-in-on-nad The Guardian